Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension
Authors:
- Enrique Diaz-GuzmanEDEnrique Diaz-Guzman
- Omar A. MinaiOMOmar A. Minai
- 1 May 2008
- journal article
- Published by Elsevier in Respiratory Medicine
- Vol. 102 (5) , 681-689
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Long-term Follow-up After Conversion from Intravenous Epoprostenol to Oral Therapy With Bosentan or Sildenafil in 13 Patients With Pulmonary Arterial HypertensionThe Journal of Heart and Lung Transplantation, 2007
- Conversion to Bosentan From Prostacyclin Infusion Therapy in Pulmonary Arterial HypertensionChest, 2006
- Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensionsAnnals of the Rheumatic Diseases, 2006
- Transition From Epoprostenol and Treprostinil to the Oral Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary HypertensionChest, 2004
- Prognosis of Pulmonary Arterial Hypertension*Chest, 2004
- Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentanThe American Journal of Cardiology, 2004
- Successful Withdrawal of Long-term Epoprostenol Therapy for Pulmonary Arterial HypertensionChest, 2003
- Flolan Infusion Interruption: A Lethal Complication during Venous AccessJournal of Vascular and Interventional Radiology, 2001
- Epoprostenol in Primary Pulmonary HypertensionAnnals of Pharmacotherapy, 1999
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996